The Power of Persistence: Monsanto's Breakthrough in Arthritis Treatment
Monsanto's innovative approach to drug research and development has yielded a significant breakthrough in the treatment of arthritis, thanks to the tireless efforts of Chief Scientist Philip Needleman. Despite conventional wisdom and the skepticism of Wall Street analysts, Monsanto invested deeply in its G.D. Searle & Co. drug subsidiary, devoting 26 percent of its budget to research and development. This gamble is paying off with the imminent release of Celebra, a new arthritis pill predicted to double Searle's sales in its first year on the market.
Key Takeaways:
- Monsanto invested 26 percent of its budget in research and development at its G.D. Searle & Co. drug subsidiary, taking a risk in pursuit of innovation.
- Philip Needleman, Chief Scientist at Monsanto, led the development of Celebra, a new arthritis pill that has the potential to revolutionize the treatment of the disease.
- Needleman's research at the Washington University School of Medicine concentrated on the complex chemicals that serve as on-off switches in the body, laying the groundwork for the discovery of Celebra.
- The conventional approach of pharmaceutical companies often prioritizes quick financial gains over basic scientific research, hindering the development of life-saving treatments.
- Needleman's story serves as a testament to the importance of persistence and investing in basic scientific research, which can yield more effective and life-changing treatments.
Statistics:
- 26 percent: the percentage of Monsanto's budget devoted to research and development at its G.D. Searle & Co. drug subsidiary.
- 30 years: the amount of time Philip Needleman spent researching and developing Celebra, from his early days at the Washington University School of Medicine.
- 100%: the potential increase in sales for Searle in its first year on the market if Celebra is successful.
Sources:
Washington Post
Time Magazine
Washington University School of Medicine
Monsanto Annual Report